<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p62" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_62{left:130px;bottom:1196px;letter-spacing:-0.15px;}
#t2_62{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_62{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_62{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_62{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_62{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_62{left:238px;bottom:1003px;letter-spacing:-0.01px;}
#t8_62{left:238px;bottom:968px;letter-spacing:-0.01px;}
#t9_62{left:238px;bottom:949px;letter-spacing:-0.01px;}
#ta_62{left:128px;bottom:880px;letter-spacing:-0.18px;}
#tb_62{left:238px;bottom:880px;letter-spacing:-0.2px;}
#tc_62{left:258px;bottom:855px;letter-spacing:0.02px;}
#td_62{left:141px;bottom:814px;letter-spacing:-0.01px;}
#te_62{left:248px;bottom:815px;letter-spacing:0.12px;}
#tf_62{left:141px;bottom:783px;letter-spacing:0.22px;}
#tg_62{left:250px;bottom:778px;letter-spacing:-0.01px;}
#th_62{left:143px;bottom:735px;}
#ti_62{left:141px;bottom:699px;letter-spacing:-0.03px;}
#tj_62{left:248px;bottom:699px;letter-spacing:-0.03px;}
#tk_62{left:141px;bottom:652px;letter-spacing:-0.28px;}
#tl_62{left:248px;bottom:625px;letter-spacing:-0.04px;}
#tm_62{left:141px;bottom:553px;letter-spacing:-0.01px;}
#tn_62{left:248px;bottom:554px;letter-spacing:0.25px;}
#to_62{left:143px;bottom:497px;letter-spacing:-0.29px;}
#tp_62{left:250px;bottom:517px;letter-spacing:-0.01px;}
#tq_62{left:250px;bottom:497px;letter-spacing:-0.01px;}
#tr_62{left:250px;bottom:478px;letter-spacing:-0.01px;}
#ts_62{left:248px;bottom:442px;letter-spacing:-0.04px;}
#tt_62{left:238px;bottom:382px;letter-spacing:-0.01px;}
#tu_62{left:238px;bottom:363px;letter-spacing:-0.01px;}
#tv_62{left:238px;bottom:343px;letter-spacing:-0.01px;}
#tw_62{left:238px;bottom:324px;letter-spacing:-0.01px;}
#tx_62{left:238px;bottom:305px;letter-spacing:-0.01px;}
#ty_62{left:238px;bottom:285px;letter-spacing:-0.01px;}
#tz_62{left:238px;bottom:266px;letter-spacing:-0.01px;}
#t10_62{left:238px;bottom:246px;letter-spacing:-0.01px;}
#t11_62{left:238px;bottom:227px;letter-spacing:-0.01px;}
#t12_62{left:238px;bottom:207px;letter-spacing:-0.01px;}
#t13_62{left:238px;bottom:188px;letter-spacing:-0.01px;}
#t14_62{left:238px;bottom:169px;letter-spacing:-0.01px;}
#t15_62{left:238px;bottom:149px;letter-spacing:-0.01px;}
#t16_62{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_62{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_62{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_62{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
.s3_62{font-size:18px;font-family:NotoSans-Regular_7j-;color:#000;}
.s4_62{font-size:16px;font-family:NotoSans-Regular_7j-;color:#000;}
.s5_62{font-size:8px;font-family:NotoSans-Regular_7j-;color:#000;}
.s6_62{font-size:28px;font-family:NotoSans-Regular_7j-;color:#000;}
.s7_62{font-size:10px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts62" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg62Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg62" style="-webkit-user-select: none;"><object width="908" height="1286" data="62/62.svg" type="image/svg+xml" id="pdf62" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_62" class="t s0_62">7.3. Fundamental considerations of multimodal therapy approaches </span><span id="t2_62" class="t s1_62">62 </span>
<span id="t3_62" class="t s2_62">In a randomized study, a survival benefit was also observed for the simultaneous application </span>
<span id="t4_62" class="t s2_62">of cetuximab with radiotherapy [194]. In the subgroup of 107 patients with laryngeal </span>
<span id="t5_62" class="t s2_62">carcinoma, the effect of cetuximab was relatively small (hazard ratio 0.87 (CI95% [0.60-1.27]) </span>
<span id="t6_62" class="t s2_62">[199]), so that this therapy should not be used as a priority in laryngeal carcinoma. </span>
<span id="t7_62" class="t s2_62">Background to 7.20. </span>
<span id="t8_62" class="t s2_62">The HPV status of the tumors was not investigated in these studies, so that different benefits </span>
<span id="t9_62" class="t s2_62">of additional chemotherapy on HPV-positive and HPV-negative tumors cannot be ruled out. </span>
<span id="ta_62" class="t s3_62">7.3.1. </span><span id="tb_62" class="t s3_62">Special features of radiotherapy in the treatment of </span>
<span id="tc_62" class="t s4_62">Laryngeal carcinoma </span>
<span id="td_62" class="t s2_62">7.21. </span><span id="te_62" class="t s1_62">Evidence-based recommendation </span>
<span id="tf_62" class="t s5_62">Recommendation level </span>
<span id="tg_62" class="t s2_62">Radiotherapy should be performed as IMRT. </span>
<span id="th_62" class="t s6_62">B </span>
<span id="ti_62" class="t s7_62">Level of Evidence </span><span id="tj_62" class="t s7_62">[206, 207] </span>
<span id="tk_62" class="t s6_62">1a </span>
<span id="tl_62" class="t s7_62">Strong consensus: 100% </span>
<span id="tm_62" class="t s2_62">7.22. </span><span id="tn_62" class="t s0_62">Consensus-based recommendation </span>
<span id="to_62" class="t s6_62">EEC </span>
<span id="tp_62" class="t s2_62">In IMRT, the planning target volumes to be irradiated at different levels can be treated </span>
<span id="tq_62" class="t s2_62">either in the form of a simultaneously integrated boost or in the form of a sequential </span>
<span id="tr_62" class="t s2_62">boost. </span>
<span id="ts_62" class="t s7_62">Strong consensus: 100% </span>
<span id="tt_62" class="t s2_62">With the introduction of 3-dimensional cross-sectional imaging in radiation planning, the </span>
<span id="tu_62" class="t s2_62">precise contouring of target volumes and organs at risk has become possible. Modern linear </span>
<span id="tv_62" class="t s2_62">accelerators in conjunction with highly developed radiation planning programs now enable the </span>
<span id="tw_62" class="t s2_62">use of intensity-modulated radiotherapy (IMRT) in almost all radio-oncology departments and </span>
<span id="tx_62" class="t s2_62">practices, which enables significantly improved physical dose distributions. Nutting et al. [206] </span>
<span id="ty_62" class="t s2_62">were able to demonstrate in a randomized study on head and neck tumors that IMRT leads to </span>
<span id="tz_62" class="t s2_62">significantly lower acute and chronic xerostomia and subcutaneous fibrosis compared to </span>
<span id="t10_62" class="t s2_62">conventional 3D planned radiotherapy. These advantages were also associated with an </span>
<span id="t11_62" class="t s2_62">improvement in quality of life. However, fatigue syndromes were observed more frequently in </span>
<span id="t12_62" class="t s2_62">the IMRT arm, presumably due to the slightly higher dose in the posterior cranial fossa as a </span>
<span id="t13_62" class="t s2_62">consequence of the differently weighted radiation directions to protect the parotid gland in the </span>
<span id="t14_62" class="t s2_62">IMRT arm of the study. Locoregional tumor control, disease-free survival and overall survival </span>
<span id="t15_62" class="t s2_62">were not significantly different. A systematic </span>
<span id="t16_62" class="t s0_62">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
